. Author manuscript; available in PMC: 2021 Jul 21.

Published in final edited form as: Expert Rev Anticancer Ther. 2020 Jul 21;20(7):551–561. doi: 10.1080/14737140.2020.1782201

Table 3.

Ongoing trials of novel antibody-drug conjugates in advanced urothelial cancer.

	Trial	Design	Setting	Arm(s) / Cohort(s)	Primary Endpoint(s)
Nectin-4 / Enfortumab vedotin	EV-302 (NCT04223856)	Randomized Phase III	Front-line, Cisplatin-Eligible	1) EV + Pembro 2) Gem/Cis or Gem/Carbo 3) EV + Pembro + Cis or Carbo	PFS & OS
	EV-201 (Cohort 2) (NCT03219333)	Single-Arm Phase II	Platinum-Naïve and Cisplatin-ineligible	EV monotherapy	ORR
	EV-301 (NCT03474107)	Randomized Phase III	Platinum- and Checkpoint Blockade-Refractory	1) EV monotherapy 2) Chemotherapy (docetaxel, vinflunine, or paclitaxel)	OS
	EV-103 (NCT03288545)	Multicohort Phase I/II	Multiple^*	1) EV monotherapy 2) EV + Pembro 3) EV + Pembro + (Cis or Carbo) 4) EV + Cis 5) EV + Carbo 6) EV + Gem	Safety & ORR
	MORPHEUS mUC (NCT03869190)	Multicohort Phase I/II	Platinum-Refractory	Atezo + EV	ORR
Trop-2 / Sacituzumab govitecan	TROPHY-U-01 (NCT03547973)	Single-Arm Multicohort Phase II	Checkpoint Blockade Refractory and Platinum-Refractory or Ineligible	Sacituzumab Govitecan	ORR
Her-2	NCT03523572	Multicohort Phase Ib	Platinum-Refractory	Trastuzumab Deruxtecan + Nivo	Safety & ORR
Her-2	NCT04073602	Single Arm Phase II	Chemotherapy- Refractory	RC48-ADC monotherapy	ORR

Two cohorts of MIBC will assess pCR rate